Inhibitory effects of aptamer targeted teicoplanin encapsulated PLGA nanoparticles for Staphylococcus aureus strains

Basit Öğe Kaydı
dc.contributor.authorUçak, Samet
dc.contributor.authorSudağıdan, Mert
dc.contributor.authorBorsa, Barış Ata
dc.contributor.authorMansuroğlu, Banu
dc.contributor.authorÖzalp, Veli Cengiz
dc.date.accessioned2021-05-15T11:33:43Z
dc.date.available2021-05-15T11:33:43Z
dc.date.issued2020
dc.departmentTıp Fakültesi, Tıbbi Biyoloji Anabilim Dalıen_US
dc.descriptionOzalp, Veli Cengiz/0000-0002-7659-5990; Mansuroglu, Banu/0000-0001-8440-9118; UCAK, SAMET/0000-0002-3461-2481
dc.description.abstractEmergence of resistance to traditional antibiotic treatments necessitates alternative delivery systems. Teicoplanin is a glycopeptide antibiotic used in the treatments of serious infections caused by Gram-positive bacteria, including Methicillin Resistant Staphylococcus aureus (MRSA). One strategy to keep up with antibiotic resistance development is to limit dose and amount during treatments. Targeted delivery systems of antibiotics have been suggested as a mechanism to slow-down the evolution of resistance and to increase efficiency of the antimicrobials on already resistant pathogens. In this study, we report teicoplanin delivery nanoparticles of Poly Lactic-co-Glycolic Acid (PLGA), which are functionalized with S. aureus specific aptamers. A 32-fold decrease in minimum inhibitory concentration (MIC) values of teicoplanin for S. aureus was demonstrated for susceptible strains and about 64-fold decline in MIC value was achieved for moderately resistant clinical isolates of MRSA upon teicoplanin treatment with aptamer-PLGA nanoparticles. Although teicoplanin delivery in PLGA nanoparticles without targeting demonstrated eightfold decrease in MIC of susceptible strains of S. aureus and S. epidermidis and twofold in MIC of resistant strains, the aptamer targeting specifically decreased MIC for S. aureus, but not for S. epidermidis. Therefore, aptamer-targeted PLGA delivery of antibiotic can be an attractive alternative to combat with some of the multi-drug resistant bacterial pathogens.en_US
dc.description.sponsorshipResearch Fund of the Yildiz Technical UniversityYildiz Technical University [FDK-2018-3244]en_US
dc.description.sponsorshipThis work was supported by Research Fund of the Yildiz Technical University. Project Number: FDK-2018-3244.en_US
dc.identifier.doi10.1007/s11274-020-02845-y
dc.identifier.issn0959-3993
dc.identifier.issn1573-0972
dc.identifier.issue5en_US
dc.identifier.pmid32333113
dc.identifier.scopus2-s2.0-85083826951
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1007/s11274-020-02845-y
dc.identifier.urihttps://hdl.handle.net/20.500.12939/217
dc.identifier.volume36en_US
dc.identifier.wosWOS:000528380700001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorUçak, Samet
dc.language.isoen
dc.publisherSpringeren_US
dc.relation.ispartofWorld Journal of Microbiology & Biotechnology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAntibioticsen_US
dc.subjectMRSAen_US
dc.subjectNanoparticlesen_US
dc.subjectAptamersen_US
dc.subjectStaphylococcus Aureusen_US
dc.titleInhibitory effects of aptamer targeted teicoplanin encapsulated PLGA nanoparticles for Staphylococcus aureus strains
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Temel Tıp Bilimleri Bölümü Koleksiyonu